SEC FORM 3

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Aharon Arnon

(Last)

(First)

(Middle)

12 YAVNE ST.

(Street)

TEL AVIV

6579116

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2021

3. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd. [ CMMB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to purchase American Depositary Shares	⁽¹⁾	12/03/2027	American Depositary Shares⁽²⁾	13,274	1.49	D
Option to purchase American Depositary Shares	⁽³⁾	12/16/2029	American Depositary Shares⁽²⁾	61,958	1.62	D

Explanation of Responses:

1. 10,779 of these options to purchase American Depositary Share (ADSs) have vested and are exercisable as of the date hereof, and the remaining 2,495 of these options will vest and become exercisable in three remaining installments, with 1/3 of such options vesting on each three month anniversary commencing on of June 4, 2021, subject to the Reporting Person's continued service.

2. Each ADS represents twenty (20) ordinary shares, no par value, of the Issuer.

3. 30,973 of these options to purchase ADSs have vested and are exercisable as of the date hereof, and the remaining 30,985 of these options will vest and become exercisable in eight remaining installments, with 12.5% of such options vesting on each three month anniversary commencing on May 28, 2021, subject to the Reporting Person's continued service.

Remarks:

Exhibit 24.1: Power of Attorney

	/s/ Matthew Rudolph, Esq., Attorney-in-Fact for Arnon Aharon	03/25/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 3 filed by Arnon Aharon